ACTU vs TGT · $49.0M cap vs P/E 17, rev $51.98B
Actuate Therapeutics, Inc. Common stock (ACTU) versus Target Corporation (TGT) — a side-by-side from cached financials, not a winner call.
Actuate Therapeutics, Inc. Common stock (ACTU) is a biotechnology company listed on NASDAQ.
Target Corporation (TGT) is a discount stores company listed on NYSE.
ACTU does not have a complete income-statement cache yet.
Latest reported TGT revenue for 2026-08-01 was $51.98B. Net income was $2.66B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
ACTU currently screens at market cap $49.0M. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
Not investment advice. Open the ACTU and TGT stock pages for the full models.
Not investment advice.